Immunic (IMUX) Cash from Financing Activities (2013 - 2026)

Immunic (IMUX) has 14 years of Cash from Financing Activities data on file, last reported at $188.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $188.6 million; the trailing twelve-month figure through Mar 2026 stood at $254.2 million (up 330054.55% YoY), and the FY2025 full-year result was $65.6 million, down 12.03% from the prior year.
• Cash from Financing Activities climbed to $188.6 million in Q1 2026, from $59000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $188.6 million in Q1 2026 to a low of $51000.0 in Q1 2023.
• A 5-year average of $35.5 million and a median of $5.3 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 99.83% in 2023 and surged 145907.84% in 2024, its largest moves.
• Tracing IMUX's Cash from Financing Activities over 5 years: stood at $56.0 million in 2022, then tumbled by 98.92% to $604000.0 in 2023, then sank by 87.25% to $77000.0 in 2024, then dropped by 23.38% to $59000.0 in 2025, then surged by 319632.2% to $188.6 million in 2026.
• Business Quant data shows IMUX's Cash from Financing Activities at $188.6 million in Q1 2026, $59000.0 in Q4 2025, and $65.5 million in Q2 2025.